Please assess the completion status of the following clinical trial:

Trial Title: Intraarticular Corticosteroid Therapy in Perthes Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age of 4 to 12 years~* diagnosed with Idiopathic osteonecrosis of the femoral head~* symptoms less than 12 months old.~Exclusion Criteria:~* Symptoms for more than 12 months~* Previous treatment other than anti-inflammatories, crutches or bed rest~* Subjects more than 8 years old or have a hand bone age greater than 6 years old and lateral pillar B or B/C disease.~* Bilateral hip disease~* Personal or family history of problems with general anesthesia~* Prior steroid treatment~* Previous diagnosis of:~  * Asthma~ * Identifiable rheumatologic condition~ * Metabolic Diseases (including but not limited to Gaucher's disease or congenital hypothyroidism)~ * Sickle cell disease~ * Known pain syndrome~ * Hip sepsis~ * Prior malignancy (solid organ or bone marrow transplant)~ * Blood Clotting disorder

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Injection (Type: EXPERIMENTAL): Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
- Control (Type: NO_INTERVENTION): Patients will be enrolled in physical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).